Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
IL-23R–activated STAT3/STAT4 is essential for Th1/Th17-mediated CNS autoimmunity
Priscilla W. Lee, … , Michael K. Racke, Amy E. Lovett-Racke
Priscilla W. Lee, … , Michael K. Racke, Amy E. Lovett-Racke
Published September 7, 2017
Citation Information: JCI Insight. 2017;2(17):e91663. https://doi.org/10.1172/jci.insight.91663.
View: Text | PDF
Research Article Immunology

IL-23R–activated STAT3/STAT4 is essential for Th1/Th17-mediated CNS autoimmunity

  • Text
  • PDF
Abstract

The factors that promote the differentiation of pathogenic T cells in autoimmune diseases are poorly defined. Use of genetically modified mice has provided insight into molecules necessary for the development of autoimmunity, but the sum of the data has led to contradictory observations based on what is currently known about specific molecules in specific signaling pathways. To define the minimum signals required for development of encephalitogenic T cells that cause CNS autoimmunity, myelin-specific T cells were differentiated with various cytokine cocktails, and pathogenicity was determined by transfer into mice. IL-6+IL-23 or IL-12+IL-23 generated encephalitogenic T cells and recapitulated the essential cytokine signals provided by antigen-presenting cells, and both IL-6 and IL-12 induced IL-23 receptor expression on both mouse and human naive T cells. IL-23 signaled through both STAT3 and STAT4, and disruption in STAT4 signaling impaired CNS autoimmunity independent of IL-12. These data explain why IL-12–deficient mice develop CNS autoimmunity, while STAT4-deficient mice are resistant. CD4+ memory T cells from multiple sclerosis patients had significantly higher levels of p-STAT3/p-STAT4, and p-STAT3/p-STAT4 heterodimers were observed upon IL-23 signaling, suggesting that p-STAT3/p-STAT4 induced by IL-23 signaling orchestrate the generation of pathogenic T cells in CNS autoimmunity, regardless of Th1 or Th17 phenotype.

Authors

Priscilla W. Lee, Alan J. Smith, Yuhong Yang, Amanda J. Selhorst, Yue Liu, Michael K. Racke, Amy E. Lovett-Racke

×

Figure 4

IL-23R signaling activates both STAT3 and STAT4.

Options: View larger image (or click on image) Download as PowerPoint
IL-23R signaling activates both STAT3 and STAT4.
Splenocytes from naive ...
Splenocytes from naive B10.PL mice were activated in vitro with anti-CD3/CD28 in the absence/presence of IL-23, IL-6, IL-12, or combinations for 66 hours. The cells were washed and rested in fresh medium for 4 hours and then were stimulated with either IL-23 or PBS for 30 minutes. (A and B) Cells were analyzed by flow cytometry. Gated CD4 T cells were analyzed for p-STAT3 and p-STAT4. (C) Whole cell lysate was extracted, and p-STAT3, STAT3, p-STAT4, STAT4, and β-actin levels were determined by Western blotting. (D and E) The band intensity of STAT3, STAT4, p-STAT3, and p-STAT4 were quantified by NIH ImageJ software, and no cytokine condition in the PBS group was used as reference for normalization. The ratio of phosphorylation was determined by comparing p-STAT3 to STAT3 and p-STAT4 to STAT4. The data is representative of 4 independent experiments. The a, b, and c in D and E illustrate qualitative changes in p-STAT4 (D) and p-STAT3 (E) in response to IL-23.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts